Citations

Clear

499 citation(s) found for "Tracy, PB".

Abstract P1062: Pre-Pandemic Thrombo-inflammatory Biomarkers and Risk of Severe Covid-19: the Collaborative Cohort of Cohorts for Covid-19 Research (C4R)
Cushman, Mary , Choi, Yuni , Reiner, Alex P. , Mukaz, Debora Kamin , Xanthakis, Vanessa, Johnson, Andrew D. , Umans, Jason G. , Kandula, Namratha R. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Jacobs, David R. , Demmer, Ryan T. , Tracy, Russell P. , Olson, Nels C. , Doyle, Margaret F. , Raffield, Laura M. , Min, Yuan‐I , Vasan, Ramachandran S. , Xanthakis, Vanessa , Make, Barry J. , Regan, Elizabeth Anne , Bowler, Russell P. , Thyagarajan, Bharat

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1062 Get It

Background: Thrombo-inflammation is a hallmark of acute Covid-19, with higher thrombo-inflammatory markers during infection associated with adverse outcomes. We hypothesized that higher pre-pandemic biomarkers, reflecting a higher thrombo-inflammatory setpoint, might identify people at greater risk of severe manifestations of Covid-19. Hypothesis: Pre-pandemic inflammation markers are associated with risk of hospitalized or fatal (hereafter, “severe”) Covid-19 in a multi-ethnic US sample. Methods: From 2020-2023, C4R harmonized pre-pandemic measures and ascertained Covid-19 across 14 longstanding cohort studies. In 12 cohorts, we assessed biomarker data and covariates from the study visit closest to the pandemic for 6 analytes shown in the Table. HRs of severe Covid-19 by pre-pandemic biomarkers were estimated using cause-specific Cox regression, treating non-severe Covid-19 as a competing risk, and adjusting for pre-pandemic sociodemographic and clinical characteristics. Results: Biomarkers were measured a mean of 20 years before the pandemic with different sample sizes for each (Table footnote). Mean age at the start of the pandemic was in the 60s or 70s depending on the biomarker. The most represented race or ethnic groups were White and Black. The largest sample was for C-reactive protein, and there were 1,001 severe Covid-19 cases among 38,784 participants. In the adjusted models, considered individually, higher CRP, leukocyte count, factor VIII and fibrinogen, but not other markers, were associated with greater risk of severe Covid-19 (Table).Associations were robust across subgroups and time since biomarker measurement (example for C-reactive protein in Figure). Conclusions: In this prospective multi-study analysis of a multi-ethnic population, higher basal levels of thrombo-inflammation markers were associated with greater risk of severe Covid-19. Since we considered non-severe Covid-19 as a competing risk, associations may reflect factors related to progression to more serious Covid-19 illness.
Lipotoxicity Induces β-cell Small Extracellular Vesicle–Mediated β-cell Dysfunction in Male Mice
Roy, Abhishek , Hoff, Alexandra, Ariyaratne, Gallage, Tahawi, M H D Noor, Rajagopalan, Kamalnath Sankaran, Brown, Matthew , Omori, Kazuno , Lewis-Brinkman, Sean , Nguyen, Thanh, Soto-González, Alondra , Matveyenko, Aleksey V. , Javeed, Naureen , Her, Tracy K. , Gutiérrez, Roberto-León, Peterson, Quinn P. , Javeed, Naureen , Roy, Abhishek, Gutiérrez, Roberto-León, TAHAWI, MHD NOOR

Mayo Clinic

Endocrinology | April 3, 2025 | Volume: 166 | Issue: 5 | Pages: No page available

10.1210/endocr/bqaf067 | PMID 40179251 Get It

Abstract Chronically elevated circulating excess free fatty acids (ie, lipotoxicity) is a pathological process implicated in several metabolic disorders, including obesity-driven type 2 diabetes (T2D). Lipotoxicity exerts detrimental effects on pancreatic islet β-cells by reducing glucose-stimulated insulin secretion (GSIS), altering β-cell transcriptional identity, and promoting apoptosis. While β-cell-derived small extracellular vesicles (sEV) have been shown to contribute to β-cell failure in T2D, their specific role in lipotoxicity-mediated β-cell failure remains to be elucidated. In this work, we demonstrate that lipotoxicity enhances the release of sEVs from β-cells, which exhibit altered proteomic and lipidomic profiles. These palmitate (PAL)-exposed extracellular vesicles (EVs) induce β-cell dysfunction in healthy mouse and human islets and trigger significant islet transcriptional changes, including the upregulation of genes associated with the TGFβ/Smad3 pathway, as noted by RNA sequencing. Importantly, pharmacological inhibition of the TGFβI/II receptor improved PAL EV-induced β-cell dysfunction, underscoring their involvement in activating the TGFβ/Smad3 pathway during this process. We have comprehensively characterized lipotoxic β-cell sEVs and implicated their role in inducing β-cell functional failure in T2D. These findings highlight potential avenues for therapeutic interventions targeting sEV-mediated pathways to preserve β-cell health in metabolic disorders.
An Approach to the Bone Marrow Workup and Diagnosis of Eosinophilia and Mast Cell Disorders
Reichard, Kaaren K. , George, Tracy I. , Arber, Daniel A.

Mayo Clinic

Advances in Anatomic Pathology | March 30, 2025 | Volume: 32 | Issue: 4 | Pages: 259-271

10.1097/pap.0000000000000486 | PMID 40143673 Get It

The approach to eosinophilia and mast cell disorders in the bone marrow is diverse and depends on multiple factors including access to ancillary testing, resources to support testing, type of practice setting (eg, community, remote, tertiary care center or specialized referral center for these disorders) and whether there are options for clinical trial enrollment. That said, while there are some basic principles to the workup that we can all likely agree upon, individual practice habits will need to be tailored to suit an individual setting. As such, the approach presented in this manuscript is meant to serve as a practical guide and not as dogma per se. Importantly, an in-depth discussion of individual diseases and International Consensus Classification diagnostic criteria will not be covered, as the main focus of this article is the approach to these disorders. The reader is referred to a comprehensive discussion of these diseases and diagnostic criteria in several excellent articles. While there are clear areas of overlap between eosinophilia and mast cell conditions (eg, systemic mastocytosis associated with eosinophilia, myeloid neoplasm with eosinophilia, and tyrosine kinase rearrangements), it is the authors’ opinion that it is perhaps easier to navigate these entities separately (eg, eosinophilia as one broad topic and mast cell conditions as another) and to recognize the settings in which overlap may exist and what testing might be considered. Eosinophilia and mast cell conditions will be discussed separately supplemented by generous use of figures and tables to highlight key points.
Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Demmer, Ryan T. , Wu, Christina , Sun, Yifei , Cushman, Mary , Boyle, Rebekah, Styer, Linda M. , Bell, Taison D., Anderson, Michaela R. , Schreiner, Pamela J. , Bowler, Russell, Rock, Jean M., Bievenue, Rachel, Kandula, Namratha R. , Raffield, Laura M. , Elkind, Mitchell S.V. , Ortega, Victor E. , Woodruff, Prescott G. , Oelsner, Elizabeth C. , Wu, Chaoqi , Anderson, Michaela R , Lee, Joyce S , Xanthakis, Vanessa , Pirzada, Amber , Mantis, Nicholas J , Raffield, Laura M , Oelsner, Elizabeth C , Demmer, Ryan T , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Regan, Elizabeth Anne , Make, Barry J. , Kanaya, Alka M , Wenzel, Sally E. , Coresh, Josef , Isasi, Carmen R. , Howard, Virginia J. , Cole, Shelley A. , Henderson, Joel

Mayo Clinic

Open Forum Infectious Diseases | March 20, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf123 | PMID 40124199 Get It

Abstract Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health–funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Janni, Wolfgang , Yab, Tracy C. , Cristofanilli, Massimo , Hayes, Daniel F. , Ignatiadis, Michail , Regan, Meredith M. , Alix‐Panabières, Catherine , Barlow, William E. , Gazzaniga, Paola , Gisbert‐Criado, Rafael , Jiang, Zefei , Magbanua, Mark Jesus M. , Mavroudis, Dimitriοs , Müller, Volkmar , Pierga, Jean‐Yves , Rack, Brigitte , Riethdorf, Sabine , Sleijfer, Stefan , Smerage, Jeffrey B. , Stebbing, Justin , Vidal-Martínez, José , Liu, Minetta C. , Friedl, Thomas W P , Yab, Tracy C , Bidard, Francois-Clément , Cristofanilli, Massimo , Hayes, Daniel F , Ignatiadis, Michail , Regan, Meredith M , Alix-Panabieres, Catherine , Barlow, William E , Caldas, Carlos , Carey, Lisa A , Dirix, Luc , Fehm, Tanja , García-Sáenz, José A , Gazzaniga, Paola , Generali, Daniele , Gerratana, Lorenzo , Gisbert-Criado, Rafael , Jacot, William , Jiang, Zefei , Joosse, Simon A , Lianidou, Evi , López López, Rafael , Magbanua, Mark J M , Manso Sanchez, Luis , Mavroudis, Dimitris , Müller, Volkmar , Munzone, Elisabetta , Pantel, Klaus , Pierga, Jean-Yves , Rack, Brigitte , Riethdorf, Sabine , Rugo, Hope S , Sideras, Kostandinos , Sleijfer, Stefan , Smerage, Jeffrey , Stebbing, Justin , Terstappen, Leon W M M , Vidal-Martínez, Jose , Wallwiener, Markus , Giridhar, Karthik V , Liu, Minetta , Caldas, Carlos , Carey, Lisa A. , Fehm, Tanja , García-Sáenz, José Á. , Joosse, Simon A. , Manso, Luís , Rugo, Hope S. , Sideras, Kostandinos , Terstappen, Leon W.M.M. , Giridhar, Karthik V.

Mayo Clinic

Clinical Cancer Research | March 18, 2025 | Volume: 31 | Issue: 11 | Pages: 2196-2209

10.1158/1078-0432.ccr-24-3108 | PMID 40100138 Get It

Abstract Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different breast cancer subtypes and clinical settings. Experimental Design: In total, 4,436 individual patient-level data with CTC results from both baseline and one follow-up (CellSearch; Menarini Silicon Biosystems) were analyzed to evaluate the association between CTC detection and overall survival (OS) in the full patient cohort and separately for tumor and treatment types. Results: Using the cutoff ≥1 CTC for CTC positivity, 913 (20.6%) patients had 0 CTCs at both time points (neg/neg) and 325 (7.3%) and 1,189 (26.8%) patients converted from CTC negative to CTC positive (neg/pos) or vice versa (pos/neg), whereas 2,009 (45.3%) patients had at least one CTC at both time points (pos/pos). The median OS for the neg/neg, neg/pos, pos/neg, and pos/pos group was 45.6, 26.1, 32.3, and 17.3 months, respectively (P < 0.0001, global log-rank test). CTC responders (pos/neg) showed a lower risk of death compared with CTC nonresponders (pos/pos; HR, 0.48; 95% confidence interval, 0.44–0.53). Similar results were obtained in subgroup analyses according to hormone receptor and HER2 subtype, treatment type, and with a ≥5 CTC cutoff for CTC positivity. Conclusions: Follow-up CTC assessments strongly predict OS independently from tumor subtype and treatment. New randomized trials to define the clinical utility of CTC monitoring for risk stratification and as an early response marker in metastatic breast cancer are urgently needed.
Gluten‐free schooling: Navigating challenges and triumphs for children with celiac disease
Weisbrod, Vanessa , Khavari, Nasim, Absah, Imad , Mallon, Danny, Raber, Catherine , Badalyan, Vahe , Shull, Mary , Dunn, Ashley R., Wren, Anava, Mardini, Farah, Fahey, Lisa M. , Ediger, Tracy , Leonard, Maureen M. , López-Rivera, Javier A. , Jericho, Hilary , Jericho, Hilary , Weisbrod, Vanessa , Lee, Dale Young , Verma, Ritu , Dunn, Ashley, Silvester, Jocelyn A.

Mayo Clinic

JPGN Reports | March 11, 2025 | Volume: 6 | Issue: 2 | Pages: 99-106

10.1002/jpr3.70013 | PMID 40386317 Get It

ABSTRACTObjectivesCeliac disease (CeD), an autoimmune disorder triggered by gluten ingestion, induces intestinal inflammation and varied symptoms. Treatment entails a strict gluten‐free diet (GFD), posing challenges for students, especially in schools with limited food choices. Nonadherence worsens symptoms, yet research on CeD's impact on students is scarce.MethodsThe CeliacKIDS study, conducted across 11 United States academic medical centers, evaluated gluten exposure risk in pediatric CeD patients via a cross‐sectional survey from August 2020 to August 2021. Participants recruited from treating institutions were approved by respective Institutional Review Boards.ResultsOne hundred and sixty children aged 5–18 (65% female, 34% male, 1% other) participated. Only 12% had GF food options at school, 31% brought their own for celebrations, and 41% lacked gluten free (GF) snacks after school. Thirty‐six percent lacked a 504 plan, with 5% misinformed. Hand hygiene concerns included 24% using sanitizer and 10% rarely washing hands before eating. Sixty‐two percent disclosed CeD, 35% when prompted, and 3% refused, mainly 13‐year‐old males. Two percent hesitated to request GF options, and 2% consumed potentially gluten‐containing food from friends.ConclusionMany US schools provide GF accommodations under the Americans with Disabilities Act (ADA) but lack national standards. Diverse GF options and education on GF‐safe practices are crucial for GFD adherence. Discrepancies in parent–child perceptions emphasize the need for better communication. Adolescents, particularly females aged 12–13 with 2+ years on a GF diet, face higher risks. Transparent family–school communication is vital for optimizing the school experience and ensuring GFD adherence. Comprehensive nationwide school training is essential for celiac patients' well‐being.
Verdiperstat in Amyotrophic Lateral Sclerosis
Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel, Chen, Hao-Wun, Nm, Mathai, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martín, Alan, Greene, Ericka , Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew B. , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep , Walk, David , Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny A. , Soliven, Betty , Roos, Raymond, Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Fournier, C. , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, Liam, Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patterson, J.C., Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, M., Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Santiago, Diana De, Félix, Adrián, Garrett, Karly, Hamilton, Jenny, Khan, Kamran, Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Andrews, Jinsy , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joseph , Young, Eufrosina , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alex, Hall, Meghan, Kittle, Gale, Connolly, Mariah, D’Agostino, Derek, Tustison, Eric, Scirocco, Erica, Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Heitzman, Daragh, Ajroud‐Driss, Senda , Appel, Stanley H. , Shroff, Sheetal , Katz, Jonathan, Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Miller, Timothy M. , Fernandes, Joseph Americo, Ilieva, Hristelina , Jawdat, Omar, Weiss, Michael D. , Foster, Laura A. , Owegi, Margaret, Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Fee, Dominic , Lewis, Richard A. , Rosenfeld, Jeffrey , Johnson, Kristin, Elliott, Matthew, Kasarskis, Edward J. , Rutkove, Seward B. , McIlduff, Courtney, Bedlack, Richard , Elman, Lauren , Goyal, Namita , Rezania, Kourosh , Twydell, Paul, Benatar, Michael , Glass, Jonathan D. , Jones, Vovanti , Zilliox, Lindsay , Wymer, James , Beydoun, Said R., Shah, Jaimin , Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Nayar, Shakti, Donohue, Mary V., Grossman, Katheryn, Campbell, Daniel , Qureshi, Irfan , Babu, Suma , Group, HEALEY ALS Platform Trial Study, Maragakis, Nicholas J. , Scirocco, Erica , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Maragakis, Nicholas , Bedlack, Richard S , Walk, David , Hayden, Douglas, Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Robbins, Nathaniel M. , Oskarsson, Björn , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Estes, Michaela, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Kolvek, Taylor, Korin, Alexander, Nguyen, Joey, Novak, Ilya, Ostrow, Joe, Palillo, Jack, Patel, Payal, Patterson, Janae, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Felix, Adrian, Khan, Kamran, Lovett, Marlee, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Ladha, Shafeeq , Newman, Daniel S., Swenson, Andrea , Caress, James B. , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Granit, Volkan , Donohue, Mary, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study

Mayo Clinic

JAMA Neurology | February 17, 2025 | Volume: 82 | Issue: 4 | Pages: 333

10.1001/jamaneurol.2024.5249 | PMID 40067754 Get It

ImportanceMyeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via reduced neuroinflammation and oxidative stress.ObjectiveTo determine the safety, tolerability, and efficacy of verdiperstat, a selective myeloperoxidase inhibitor, in ALS.Design, Settings, and ParticipantsVerdiperstat was tested as a regimen of the HEALEY ALS Platform Trial, a multicenter, double-blind, perpetual platform design, randomized clinical trial, with sharing of trial infrastructure and placebo data across multiple regimens. The study was conducted at 54 ALS referral centers across the US from July 2020 to April 2022. Adult participants with a diagnosis of clinically possible, probable, laboratory-supported probable, or definite ALS defined by the revised El Escorial criteria were randomized to verdiperstat or regimen-specific placebo. An additional group of participants concurrently randomized to placebo from other regimens was included in the analyses.InterventionsEligible participants were randomized in a 3:1 ratio to receive oral verdiperstat, 600 mg, twice daily or matching placebo for a planned placebo-controlled duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in disease severity, as measured by a joint model of ALS Functional Rating Scale–Revised and survival, with the treatment effect quantified by the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression of verdiperstat relative to placebo.ResultsA total of 167 participants (mean [SD] age, 58.5 [11.4] years; 59 [35.3%] female; 108 [64.6%] male) were randomized to either verdiperstat (126 [75.4%]) or to placebo (41 [25.6%]). Among the participants randomized to the verdiperstat regimen, 130 (78%) completed the trial. The estimated DRR was 0.98 (95% credible interval, 0.77-1.24; posterior probability = 0.57 for slowing of disease progression [DRR <1]). Verdiperstat was estimated to slow progression by 2% vs placebo (95% credible interval, −23% to 24%; posterior probability 0.57). Verdiperstat was overall safe and well tolerated. Common adverse events in the verdiperstat group were nausea, insomnia, and elevated thyrotropin levels.Conclusions and RelevanceResults demonstrate that treatment with verdiperstat was unlikely to alter disease progression in ALS.Trial RegistrationClinical Trial Identifiers: NCT04297683 and NCT04436510
Pridopidine in Amyotrophic Lateral Sclerosis
Hayden, Douglas, Lai, Po-Ying, Donahue, Rachel, Chen, H.Y., Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Glass, Jonathan D. , Fournier, Christina , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Heiman‐Patterson, Terry , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Ajroud‐Driss, Senda , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H. , Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael , Jones, Vovanti , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Leitner, Melanie , Chen, Kelly , Goldberg, Y. Paul, Cohen, Yaël C. , Geva, Michal , Hayden, Michael R. , Group, HEALEY ALS Platform Trial Study, Scirocco, Erica , Martinez-Thompson, Jennifer, Simmons, Zachary , Bedlack, Richard S , Walk, David , Wang, Jianing , Mathai, N. M., Kolb, Stephen J. , Szymanski, April L., Martin, Alan, Liao, Bing, Arneklev, JinAe, Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Dimachkie, Mazen M. , Ghasemi, Mehdi , Houmani, Hajar, Pasinelli, Piera , Milliard, Jourdan, Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Shrilla, David, Rakočević, Goran , Quinn, Colin , Borg, David, Bhuvaneswaran, Karthikeyan, Kaur, Jasdeep, Rutkove, Seward B. , Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Chuquilin, Miguel , McNeely, Whitney, Bobenhouse, James, Staff, Nathan P. , Arroyave, Luisa, Bulat, Allison , Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Figueroa-Szostek, Precious, Garozzo, Tessa, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel, Irwin, Liam, Kolvek, Taylor, Korin, Alexander, Ostrow, Joe, Palillo, Jack, Phan, Minh, Proueng, Serena, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Garrett, Karly, Nelson, Linda, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed, Woodcook, Joan, Kennedy, Julie, Shefner, Jeremy M. , Oskarsson, Björn , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Berry, James D. , Babu, Suma , Giacomelli, Elisa , Maragakis, Nicholas J. , Mill, Jonathan , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Goldberg, Y. Paul, Paganoni, Sabrina , Cudkowicz, Merit

Mayo Clinic

JAMA | February 17, 2025 | Volume: 333 | Issue: 13 | Pages: 1128

10.1001/jama.2024.26429 | PMID 40067755 Get It

ImportanceAmyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention.ObjectiveTo determine the effects of pridopidine, a σ1-receptor agonist, in ALS.Design, Settings, and ParticipantsPridopidine was tested as a regimen of the HEALEY ALS Platform Trial, a phase 2/3, multicenter, randomized, double-blind, platform trial. The study was conducted at 54 sites in the US from January 2021 to July 2022 (final follow-up, July 14, 2022). A total of 163 participants with ALS were randomized to receive pridopidine or placebo. An additional 122 concurrently randomized participants were assigned to receive placebo in other regimens and included in the analyses.InterventionsEligible participants were randomized 3:1 to receive oral pridopidine 45 mg twice daily (n = 121) or matching oral placebo (n = 42) for a planned duration of 24 weeks.Main Outcomes and MeasuresThe primary efficacy outcome was change from baseline through week 24 in ALS disease severity, analyzed using a bayesian shared parameter model, which has components for function (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R]) and survival that were linked through an integrated estimate of treatment-dependent disease slowing across these 2 components. This was denoted as the disease rate ratio (DRR), with DRR less than 1 indicating a slowing in disease progression on pridopidine relative to placebo. There were 5 key secondary end points: time to 2-point or greater reduction in ALSFRS-R total score among participants with bulbar dysfunction at baseline, rate of decline in slow vital capacity among participants with bulbar dysfunction at baseline, percentage of participants with no worsening in the ALSFRS-R bulbar domain score, time to 1-point or greater change in the ALSFRS-R bulbar domain score, and time to death or permanent assisted ventilation.ResultsAmong 162 patients (mean age, 57.5 years; 35% female) who were randomized to receive the pridopidine regimen and included in the primary efficacy analysis, 136 (84%) completed the trial. In the primary analysis comparing pridopidine vs the combined placebo groups, there was no significant difference between pridopidine and placebo in the primary end point (DRR, 0.99 [95% credible interval, 0.80-1.21]; probability of DRR <1, 0.55) and no differences were seen in the components of ALSFRS-R or survival. There was no benefit of pridopidine on the secondary end points. In the safety dataset (pridopidine, n = 121; placebo, n = 163), the most common adverse events were falls (28.1% vs 29.3%, respectively) and muscular weakness (24.0% vs 31.7%, respectively).Conclusions and RelevanceIn this 24-week study, pridopidine did not impact the progression of ALS.Trial RegistrationClinicalTrials.gov Identifiers: NCT04297683, NCT04615923
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
Fournier, Christina , Quintana, Melanie , Saville, Benjamin R. , Detry, Michelle A. , Vestrucci, Matteo, Marion, Joe , Ajroud‐Driss, Senda , Chase, Marianne, Pothier, Lindsay , Harkey, Brittney, Yu, Hong , Sherman, Alexander , Hall, Meghan, Kittle, Gale, Babu, Suma , Andrews, Jinsy , D’Agostino, Derek, Tustison, Eric, Scirocco, Erica , Alameda, Gustavo, Locatelli, Eduardo, Ho, Doreen , Quick, Adam , Katz, Jonathan, Heitzman, Daragh, Appel, Stanley H., Shroff, Sheetal , Felice, Kevin J. , Maragakis, Nicholas J., Simmons, Zachary , Miller, Timothy M. , Olney, Nicholas , Weiss, Michael D. , Fernandes, Joseph Americo, Jawdat, Omar, Owegi, Margaret, Foster, Laura A. , Ilieva, Hristelina , Newman, Daniel S. , Arcila-Londono, Ximena , Jackson, Carlayne E. , Heiman‐Patterson, Terry , Lewis, Richard A. , Fee, Dominic , Elliott, Matthew, Bedlack, Richard , Kasarskis, Edward J. , Elman, Lauren , Rosenfeld, Jeffrey , Walk, David , McIlduff, Courtney, Twydell, Paul, Young, Eufrosina , Johnson, Kristin, Rezania, Kourosh , Goyal, Namita , Benatar, Michael, Jones, Vovanti , Glass, Jonathan D. , Shah, Jaimin , Beydoun, Said R., Wymer, James , Zilliox, Lindsay , Nayar, Shakti, Pattee, Gary L. , Martinez‐Thompson, Jennifer M. , Patel, Shital , Mahoney, Paul, Duda, Petra W., Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Lai, Po-Ying, Donahue, Rachel A., Chen, Hao-Wun, Mathai, Nithya, Lopes, Gabriela, McCaffrey, Alexandra, Scalia, Jennifer , Luppino, Sarah , Lagier‐Tourenne, Clotilde , Sadri‐Vakili, Ghazaleh , Heintzman, Sarah, Sufit, Robert , Szymanski, April, Jenkins, Liberty, Martin, A. D. , Greene, Ericka , Thonhoff, Jason R., Liao, Bing , Whitaker, Charles H. , Clawson, Lora , Uchil, Alpa, Riley, Kristen M., Arneklev, JinAe, Grogan, James , Su, Xiaowei , Mamarabadi, Mansoureh , Malcolm, Amber, Bazan, Tracy, Rad, Nassim, Wang, Leo H. , Piccione, Ezequiel, Thaisetthawatkul, Pariwat , Farmakidis, Constantine , Jabari, Duaa, Pasnoor, Mamatha , Dimachkie, Mazen M. , Brown, Robert H. , Ghasemi, Mehdi, Houmani, Hajar, Douthwright, Catherine, Daniello, Kate, Suresh, Niraja, Farias, Jerrica, Chen, I-Hweii A. , Steijlen, Kara , Bhavaraju‐Sanka, Ratna, Jacobsen, Bill , Milliard, Jourdan, Bowser, Robert , Deboo, Anahita, Cartwright, Michael S. , Nance, Christopher , Yasek, Julia , Harms, Matthew , Burford, Matthew, Shrilla, David, Jones, Sarah , Solórzano, Guillermo, Li, Xiaoyan , Mahuwala, Zabeen , Kumaraswamy, Vishakhadatta Mathur, Baer, Michael , Bhuvaneswaran, Karthikeyan, Maiser, Sam , Rutkove, Seward B. , Mundwiler, Andrew, Meyer, Jenny, Soliven, Betty , Roos, Raymond P. , Habib, Ali A. , Mozaffar, Tahseen , Korb, Manisha Kak , Mullen, Jeffrey, Stommel, Elijah W. , Carberry, Nathan , Govindarajan, Raghav , Darki, Leila, Rodriguez, Rodrigo , McNeely, Whitney, Diaz‐Abad, Montserrat , Jin, Peter H., Chauhan, Chandana, Bobenhouse, James, Staff, Nathan P. , Hayat, Ghazala , Bailey, Abbey, Bailey, Jesse, Barlow, Victoria , Bulat, Allison, Changkuon, Genevive, Cirino, Melissa, Deignan, Cristina, Deirmendjian, Emma, Mattos, Annette De, DiStefano, Sofia, Drake, Kristin, Estes, Michaela, Faulconer, Kenneth, Figueroa-Szostek, Precious, Garozzo, Tessa, Hasenoehrl, Meredith Gibbons, Henrique, Jennifer, Henrique, Natalie, Hurwitz, Samuel , Igne, Courtney, Irwin, L. R., Jentoft, Katie, Jordan, Boglarka, Katsovskiy, Igor, Kharakozova, Olga, Kolvek, Taylor, Korin, Alexander, La, Thuong, Li, Haining , Nguyen, Joey, Novak, Ilya, Ortiz, Ricardo, Ostrow, Joe, Pagliaro, Jaclyn , Palillo, Jack, Patel, Payal , Patterson, Janae, Phan, Minh , Popel, Najla , Proueng, Serena, Rosenthal, Jesse, Small, Catherine B. , Tarasenko, Natalia, Thomas, Mirna, Vigneswaran, Prasha, Wahab, Yusra, Whitworth, Isaac, Wright, Spencer, Connolly, Mariah, Santiago, Diana De, Felix, A. John William , Garrett, Karly, Hamilton, Jenny, Khan, Kamran , Lovett, Marlee, Nelson, Linda S., Pabon, Marissa, Rede, Diana, Bolger, Patrick, Fetouh, Ahmed , Woodcook, Joan, Kamp, Cornelia , Kennedy, Julie, McGarry, Andrew , Torti, Margherita , Maragakis, Nicholas J. , Martinez-Thompson, Jennifer, Scirocco, Erica , Simmons, Zachary , Staff, Nathan P , Maragakis, Nicholas , Bedlack, Richard S , Dimachkie, Mazen M , Walk, David , Paganoni, Sabrina , Macklin, Eric A. , Chibnik, Lori Beth , McGlothlin, Anna , Shefner, Jeremy M. , Berry, James D. , Giacomelli, Elisa , Appel, Stanley H. , Goutman, Stephen A. , Fernandes, J. Americo, Vu, Tuan , Newman, Daniel S., Ladha, Shafeeq , Caress, James B. , Swenson, Andrea , Peltier, Amanda , Johnson, Kristin, Cohen, Jeffrey Allen , Harvey, Brittany, Mahoney, Paul, Cudkowicz, Merit , Group, HEALEY ALS Platform Trial Study, Hayden, Douglas * deceased, Donahue, Rachel A., Chen, Hao-Wun, Wang, Jianing, Mathai, N. M., Kolb, Stephen J. , Szymanski, April, Martin, Alan, Liao, Bing, Riley, Kristen M., Malcolm, Amber, Feldman, Eva L. , Statland, Jeffrey , Ghasemi, Mehdi , Pasinelli, Piera , Gutmann, Ludwig , Harms, Matthew B. , Diaz, Frank , Rakočević, Goran , Quinn, Colin , Borg, David, Kaur, Jasdeep, Rao, Pooja, Robbins, Nathaniel M. , Granit, Volkan , Oskarsson, Björn , Chuquilin, Miguel , Arroyave, Luisa, Bailey, Abbey, Bulat, Allison , Hurwitz, Samuel, Irwin, Liam, Jordan, Boglarka, Korin, Alexander, Novak, Ilya, Patterson, Janae, Phan, Minh, Rosenthal, Jesse, Small, Catherine, Thomas, Mirna, Wahab, Yusra, Wright, Spencer, Garrett, Karly, Lovett, Marlee, Nelson, Linda, Pabon, Marissa, Bolger, Patrick, Fetouh, Ahmed, Kennedy, Julie

Mayo Clinic

JAMA Network Open | February 17, 2025 | Volume: 8 | Issue: 2 | Pages: e2459058

10.1001/jamanetworkopen.2024.59058 | PMID 39960672 Get It

Importance The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective To determine the effects of zilucoplan, an inhibitor of complement C5, in individuals with ALS. Design, Setting, and Participants Zilucoplan was tested as regimen A of the HEALEY ALS Platform Trial, a phase 2 to 3 multicenter, randomized, double-blind, placebo-controlled perpetual platform clinical trial with sharing of trial infrastructure and placebo data across multiple regimens. Regimen A was conducted from August 17, 2020, to May 4, 2022. A total of 162 participants were randomized to receive zilucoplan (122 [75.3%]) or regimen-specific placebo (40 [24.7%]). An additional 124 concurrently randomized participants were randomized to receive placebo in other regimens. Interventions Eligible participants were randomized in a 3:1 ratio to receive zilucoplan or matching placebo within strata of edaravone and/or riluzole use for a planned duration of 24 weeks. Active drug (zilucoplan, 0.3 mg/kg) and placebo were provided for daily subcutaneous dosing. Main Outcomes and Measures The primary end point was change in disease severity from baseline through 24 weeks as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) total score and survival, analyzed using a bayesian shared-parameter model and reported as disease rate ratio (DRR; <1 indicating treatment benefit). The study included prespecified rules for early stopping for futility. Outcome analyses were performed in the full analysis set comparing the zilucoplan group with the total shared placebo group (n = 164). Results Among the 162 participants who were randomized (mean [SD] age, 59.6 [11.3]; 99 [61.1%] male), 115 (71.0%) completed the trial. The estimated DRR common to ALSFRS-R and survival was 1.08 (95% credible interval, 0.87-1.31; posterior probability of superiority, 0.24). The trial was stopped early for futility. No unexpected treatment-related risks were identified. Conclusions and Relevance In this randomized clinical trial of zilucoplan in ALS, treatment did not alter disease progression. The adaptive platform design of the HEALEY ALS Platform Trial made it possible to test a new investigational product with efficient use of time and resources. Trial Registration ClinicalTrials.gov Identifier: NCT04297683